Transcription factor stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo

Molecular Cancer Therapeutics

Volumn 10, Issue 2, 2011, Pages 347-359

  Thomas, Christian ^a,b   Zoubeidi, Amina ^a   Kuruma, Hidetoshi ^a   Fazli, Ladan ^a   Lamoureux, Francois ^a   Beraldi, Eliana ^a   Monia, Brett P ^c   MacLeod, A Robert ^c   Thüroff, Joachim W ^b   Gleave, Martin E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; LUCIFERASE; METRIBOLONE; PROTEASOME; STAT5 PROTEIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CASTRATION; CELL GROWTH; CELL STRAIN LNCAP; GENE SILENCING; GLEASON SCORE; HORMONE RECEPTOR TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; TISSUE MICROARRAY; TRANSACTIVATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951826165     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0850     Document Type: Article

References (38)

1. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80. (Pubitemid 350166735)
2. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. AUA prostate cancer clinical guideline update panel. Guideline for the management of clinically localized prostate cancer 2007 update. J Urol 2007;177:2106-31. (Pubitemid 46726449)
3. Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther 2006:28: 1485-508. (Pubitemid 44841984)
4. Gleave ME, Bruchovsky N, Moore MJ, Venner P. Prostate cancer: 9. Treatment of advanced disease. Can Med Assoc J 1999;160:225-32.
5. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 1998;160: 1220-9. (Pubitemid 29480485)
6. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61. (Pubitemid 46211563)
7. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26:263-73. (Pubitemid 29228223)
8. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004;59:337-49. (Pubitemid 38509767)
9. Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC. Pglycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate 2004;59:77-90. (Pubitemid 38387845)
10. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone- repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000;60:2547-54. (Pubitemid 30262451)
11. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004;64:6595-602. (Pubitemid 39297919)
12. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-8. (Pubitemid 29493968)
13. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 2004;92:265-71. (Pubitemid 40128247)
14. Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, et al. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res 2008;14:5769-77.
15. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000;141:2257-65. (Pubitemid 32274381)
16. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23:1-9. (Pubitemid 40425164)
17. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010;16:1088-93.
18. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63:3575-84. (Pubitemid 36793038)
19. Hadaschik BA, Gleave ME. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 2007;25:413-9.
20. Ahonen T, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, et al. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 2003;278:27287-92. (Pubitemid 36876886)
21. Kazansky AV, Spencer DM, Greenberg NM. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res 2003;63: 8757-62. (Pubitemid 38064054)
22. Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of stranscription-5a/b signaling pathway. Endocrinology 2007;148:3089-101. (Pubitemid 46996970)
23. Dagvadorj A, Kirken RA, Leiby B, Karras J, Nevalainen MT. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res 2008;14:1317-24. (Pubitemid 351413910)
24. Li H, Ahonen T, Alanen K, et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 2004;64:4774-82. (Pubitemid 38924520)
25. Li H, Yhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. ClinCancerRes2005;11:5863-8.
26. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, et al. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 2008;68:236-48. (Pubitemid 351380125)
27. Nevalainen MT, Ahonen TJ, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, et al. Epithelial defect in prostates of Stat5a-null mice. Lab Invest 2000;80:993-1006. (Pubitemid 30483218)
28. Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 2004;10:26-7. (Pubitemid 38524693)
29. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen leves increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6047-15.
30. Leung SY, Jackson J, Miyake H, Burt H, Gleave ME. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotis regression of androgen-independent LNCaP prostate tumors. Prostate 2000;44:156-63. (Pubitemid 30419190)
31. Tan SH, Nevalainen MT. Signal transducer and activator of transcription 5a/b in prostate and breast cancers. Endocr Relat Cancer 2008;15:367-90. (Pubitemid 351880829)
32. Liao Y, Luty J, Nevalainen MT. Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer. Int J Biochem Cell Biol 2009:42:186-92.
33. Nevalainen MT, Valve EM, Ingleton PM, Harkonen PL. Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinology 1996;137:3078-88. (Pubitemid 26192207)
34. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 2006;66:135-45. (Pubitemid 43191235)
35. Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, et al. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol Cell Endocrinol 2004; 220:109-23.
36. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52:1598-605.
37. Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, et al. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am J Pathol 2010;4:1959-72.
38. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-79. (Pubitemid 40791489)